APLS

Apellis Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

27.970

+0.35(1.267%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

28.255

Open

27.840

VWAP

27.87

Vol

1.82M

Mkt Cap

3.53B

Low

27.430

Amount

50.84M

EV/EBITDA(TTM)

Total Shares

121.37M

3.57B

EV/OCF(TTM)

795.40

P/S(TTM)

4.58

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

200.65M

+20.29%

214.10M

+0.74%

358.80M

+82.29%

Estimates Revision

The market is revising Upward the revenue expectations for Apellis Pharmaceuticals, Inc. (APLS) for FY2025, with the revenue forecasts being adjusted by 15.13% over the past three months. During the same period, the stock price has changed by 60.38%.

Revenue Estimates for FY2025

Revise Upward

+15.13%

In Past 3 Month

Stock Price

Go Up

+60.38%

In Past 3 Month

19 Analyst Rating

28.10% Upside

Wall Street analysts forecast APLS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for APLS is 35.83 USD with a low forecast of 19.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

9 Hold

0 Sell

Moderate Buy

28.10% Upside

Current: 27.970

Low

19.00

Averages

35.83

High

60.00

28.10% Upside

Current: 27.970

Low

19.00

Averages

35.83

High

60.00

JPMorgan

NULL -> Overweight

maintain

$35 -> $37

2025-08-04

Reason

JPMorgan

Price Target

$35 -> $37

2025-08-04

maintain

NULL -> Overweight

Reason

JPMorgan raised the firm's price target on Apellis to $37 from $35 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect a December 2026 target versus 2025 previously.

JPMorgan

Anupam Rama

maintain

$35 -> $39

2025-08-03

Reason

JPMorgan

Anupam Rama

Price Target

$35 -> $39

2025-08-03

maintain

Reason

JPMorgan analyst Anupam Rama raised the firm's price target on Apellis to $39 from $35 and keeps an Overweight rating on the shares. The firm updated the company's model to reflect a December 2026 target versus 2025 previously.

Citi

Yigal Nochomovitz

Buy

maintain

$46 -> $52

2025-08-01

Reason

Citi

Yigal Nochomovitz

Price Target

$46 -> $52

2025-08-01

maintain

Buy

Reason

Citi analyst Yigal Nochomovitz raised the firm's price target on Apellis to $52 from $46 and keeps a Buy rating on the shares. The company reported a Q2 sales beat, showing that Syfovre can still grow, the analyst tells investors in a research note. The firm sees a good risk/reward at current share levels.

Raymond James

Outperform

maintain

$52 -> $50

2025-08-01

Reason

Raymond James

Price Target

$52 -> $50

2025-08-01

maintain

Outperform

Reason

Raymond James lowered the firm's price target on Apellis to $50 from $52 and keeps an Outperform rating on the shares following the Q2 earnings, citing the firm's "bullish" outlook for the newly-approved expansion indications for Empaveli and evidence the Syfovre launch is getting back on track. The Empaveli FDA label was expanded to include broad coverage of C3G and IC-MPGN patients 12 and older, which could expand the Empaveli addressable patient population by about 75%, the analyst tells investors in a research note.

Cantor Fitzgerald

Overweight

maintain

$39 -> $40

2025-08-01

Reason

Cantor Fitzgerald

Price Target

$39 -> $40

2025-08-01

maintain

Overweight

Reason

Cantor Fitzgerald raised the firm's price target on Apellis to $40 from $39 and keeps an Overweight rating on the shares. The Geographic Atrophy market is stabilizing and the launch in C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis is under way, the analyst tells investors in a research note. Cantor believes the Empaveli C3G launch will go well.

Scotiabank

Sector Perform

maintain

$20 -> $22

2025-07-30

Reason

Scotiabank

Price Target

$20 -> $22

2025-07-30

maintain

Sector Perform

Reason

Scotiabank raised the firm's price target on Apellis to $22 from $20 and keeps a Sector Perform rating on the shares. The firm is constructive on the FDA's approval of Empaveli, an immunosuppressant developed to treat paroxysmal nocturnal hemoglobinuria, and believes the company is in a good place to execute on the launch, the analyst tells investors. While the firm believes the commercial ramp of the drug may take more time than currently appreciated, Scotiabank remains positive on longer-term prospects and believes revenues in the outer years can grow to become meaningful.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Apellis Pharmaceuticals Inc (APLS.O) is -137.69, compared to its 5-year average forward P/E of -22.14. For a more detailed relative valuation and DCF analysis to assess Apellis Pharmaceuticals Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-22.14

Current PE

-137.69

Overvalued PE

1.84

Undervalued PE

-46.12

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-21.37

Current EV/EBITDA

-54.19

Overvalued EV/EBITDA

103.60

Undervalued EV/EBITDA

-146.34

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

37.58

Current PS

3.40

Overvalued PS

90.80

Undervalued PS

-15.63